Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

3419 - A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy


10 Oct 2016


Non-metastatic NSCLC and other thoracic malignancies


Quincy Siu-chung Chu


Annals of Oncology (2016) 27 (6): 493-496. 10.1093/annonc/mdw389


Q.S. Chu1, B. Markman2, N. Leighl3, L. Krug4, C. Rudin5, D. Lathers6, P. Basciano4, P.M. Fracasso7, G. Kollia8, P. Phillips9, G. Kolaitis10, D. Williams6, J. Jackson6, N. Ready11

Author affiliations

  • 1 Oncology, University of Alberta Cross Cancer Institute, T6G 1Z2 - Edmonton/CA
  • 2 Monash Cancer Centre, Monash Health, 3165 - Melbourne/AU
  • 3 Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 4 Immuno-oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 5 Oncology, Memorial Sloan-Kettering Cancer Center, New York/US
  • 6 Oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 7 Group Medical Director, Immuno-oncology/oncology, Exploratory Clinical And Translational Research, Bristol-Myers Squibb, 08540 - Princeton/US
  • 8 Biostatistics, Bristol-Myers Squibb, 08540 - Princeton/US
  • 9 Oncology Biomarkers, Bristol-Myers Squibb, 08543 - Princeton/US
  • 10 Analytical & Bioanalytical Development, Bristol-Myers Squibb, 08540 - Princeton/US
  • 11 Oncology, Duke University Medical Center, 27710 - Durham/US


Abstract 3419


Fucosyl-GM1 (Fuc-GM1), a ganglioside with abundant yet restricted expression on the cell surface of SCLCs, is a potential target for therapeutic approaches. Here we present preliminary results from a Phase 1/2 study of BMS-986012, a first-in-class fully human IgG1 monoclonal antibody with enhanced ADCC that specifically binds to Fuc-GM1, for the treatment of SCLC.


Patients (pts) with relapsed/refractory SCLC after at least one line of prior therapy were enrolled. BMS-986012 was administered IV at flat doses of 70, 160, 400, and 1000 mg every 3 weeks (wk) during dose escalation. Pharmacokinetics (PK) and anti-drug antibodies (ADA) were assessed during cycle 1.


Twenty-nine pts were treated across all doses. Median age was 63 yr (range: 26–81); 55% were female; 95% had a smoking history. Pts had received up to five lines of prior therapy; 52% had one prior line; 48% had 2 or more two prior lines. Nine pts were platinum refractory (≤3 mo from end of first line therapy to progression). No dose limiting toxicities or treatment-related grade 4 or 5 adverse events occurred. Treatment-related adverse events occurring in >10% of pts were pruritus, decreased appetite, and rash. Preliminary PK analysis suggests a linear dose-exposure relationship (Table). No ADAs were detected.

Summary of Single Dose Exposures of BMS-986012

70 mg 160 mg 400 mg 1000 mg
AUC (0–504 hr), ug*hr/mL Geom. Mean (CV), % 4434 (31) 8544 (23) 19642 (47) 44677 (23)
Cmax, ug/mL Geom. Mean (CV), % 28 (28) 74 (125) 145 (26) 348 (23)

Geom. = Geometric; CV = coefficient of variation

One confirmed complete response (CR; duration 53 wk; 70 mg dose level) and one confirmed partial response (PR; duration 17 wk; 400 mg dose level) were observed. Stable disease (SD) was reported in 4 pts. The CR and 2 SD occurred among the 9 platinum refractory pts.


BMS-986012 demonstrates a manageable safety profile and resulted in objective responses in relapsed SCLC, including platinum refractory pts. Preliminary PK analysis showed dose-proportional and linear increase in exposure with moderate to high variability. Dose expansion is currently enrolling at 400 and 1000 mg.

Clinical trial identification


Legal entity responsible for the study

Sponsored by Bristol-Myers Squibb


Sponsored by Bristol-Myers Squibb


Q.S-C. Chu: Personal fees from BMS and Lilly (advisory boards), Novartis (advisory board and consultancy), and Astra Zeneca, Merck (advisory and consultancy). Grants and personal fees from BI (Research Grant and advisory board). L. Krug: Grants from Bristol-Myers Squibb, during the conduct of the study; other from Bristol-Myers Squibb, outside the submitted work. C. Rudin: Personal fees from Bristol Myers Squibb, Celgene, Novartis, Medivation, and Merck, outside the submitted work. D. Lathers: Employee & Shareholder at BMS. P. Basciano: Personal fees from Bristol-Meyers Squibb, outside the submitted work as a Study Sponsor. P.M. Fracasso: Employee of BMS. P. Phillips: Employee of Bristol-Myers Squibb. N. Ready: Personal fees from Bristol Myers Squibb, Celgene, Novartis, Medivation, and Merck, outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings